| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Women |
| Source | Compounding Finder |
| URL | compoundingfinder.com/blog/testosterone-for-women (opens in a new tab) |
Specific claim evaluated
The best-supported use of testosterone in women is distressing low sexual desire after menopause; current evidence does not support prescribing it for mood, energy, cognition, muscle or bone alone, and there is no FDA-approved product for women.
Primary research supporting or contradicting the claim
The global consensus statement identifies postmenopausal hypoactive sexual desire disorder as the only evidence-based indication (Davis et al., 2019). Randomized trials show more acne and hair growth with testosterone than placebo (Islam et al., 2019).
Corrected evidence-based interpretation
The article is correct.
Rationale for grade
The page states the indication, regulatory status, need for laboratory monitoring and common androgenic adverse effects accurately, and notes that compounded products are not FDA-reviewed for potency. The publisher refers patients to compounding pharmacies, but the evaluated claims are consistent with the evidence.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID
Supporting excerpt: "Testosterone is effective for postmenopausal women with low sexual desire causing distress"